Ustekinumab biosimilar reports in Define and Refine

With the release of several Ustekinumab biosimilars in the last months we have added new reports to the ‘Biosimilars’ node in Define and Refine.

As with other biosimilar roll outs, we can easily report on the status when there is a clear definition of the brand in your drug descriptor. ‘Unknown’ means that we have an ambiguous description which we cannot interpret accurately.